- Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
- Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
- GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
- The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.
According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://cnw.fm/5ROKd). Studies showed a massive spike in overall…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
